TP53 and neoplasm: The comparison analysis presented in Fig. 5E, F shows clinically relevant mutations in PDX35 in the diagnostic stage before tumor resection, including CCND3 amplification, DAXX C629fs*16, NKX2-1 amplification, TP53 F212fs*34, and VEGFA amplification.